March 6 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd:
* BIOHAVEN ENROLLS FIRST PATIENT IN PHASE 3 CLINICAL TRIAL TO EVALUATE RIMEGEPANT ZYDIS® ODT IN THE ACUTE TREATMENT OF MIGRAINE
* BIOHAVEN - CONTINUES TO EXPECT TOPLINE RESULTS FROM TWO PHASE 3 TRIALS EXAMINING EFFICACY OF RIMEGEPANT 75 MG ORAL TABLET VERSUS PLACEBO BY END OF Q1 2018
* BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD SAYS EXPECTS TOPLINE RESULTS FROM PHASE 3 TRIAL WITH RIMEGEPANT ZYDIS(®) ODT IN Q4 OF 2018 Source text for Eikon: Further company coverage: